- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02237313
Identification of Vulnerability Factors in the Course of Pemphigus Patients (SHS-Pemphigus)
August 29, 2017 updated by: University Hospital, Rouen
Identification of Vulnerability Factors in the Course of Pemphigus Patients - SHS Pemphigus Clinical Trial
The bullous pemphigoid treatment is based on corticosteroids continued for several years.
Pemphigus causes some patients a psychological impact and sometimes major vulnerability that can occur not only at diagnosis but also at later stages of disease progression.
Our hypothesis is that these episodes of vulnerability may be under four kinds of factors that may be connected to the plurality of the history of these patients, and the resources they can mobilize throughout this experience, generating inequality in management and "work" around the disease.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The originality of the project lies in its multidisciplinary approach (dermatology, psychology, sociology).
No such study has yet been carried out in the pemphigus who has been the subject of a very small number of works in sociology or psychology.
The only studies are studies of quality of life with no longitudinal follow-up.
The perspective of qualitative and quantitative data, sociological and psychological approaches, should allow more innovative and adapted to the medico-social and psychological care of patients with pemphigus approaches.
The purpose of this study is to identify the determinants leading to moments of vulnerability in the course of patients with pemphigus in order to be able to offer preventive or corrective actions to improve the experience of the disease.
Study Type
Interventional
Enrollment (Anticipated)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Pascal JOLY, Professor
- Phone Number: +33 2 32 88 68 41
- Email: pacal.joly@chu-rouen.fr
Study Locations
-
-
-
Bobigny, France, 93000
- Recruiting
- Hôpital Avicenne
-
Contact:
- Catherine PROST-SQUARCIONI, Professor
- Phone Number: +33 1 48 95 77 07
- Email: catherine.prost@avc.aphp.fr
-
Principal Investigator:
- Catherine PROST-SQUARCIONI, professor
-
Clermont-Ferrand, France, 63003
- Recruiting
- CHU de Clermont-Ferrand Hôpital d'Estaing
-
Contact:
- Michel D'Incan, professor
- Phone Number: +33 4 73 75 05 50
- Email: mdincan@chu-clermontferrand.fr
-
Principal Investigator:
- Michel D'Incan, Professor
-
Lille, France, 59037
- Recruiting
- Chru de Lille Hopital Claude Huriez
-
Contact:
- Emmanuel DELAPORTE, Professor
- Phone Number: +33 3 20 44 41 91
- Email: Emmanuel.Delaporte@chru-lille.fr
-
Principal Investigator:
- Emmanuel DELAPORTE, Professor
-
Marseille, France
- Recruiting
- Hôpital La Timone, Assistance publique hôpitaux de Marseille-Aix
-
Contact:
- Marie-Aleth RICHARD LALLEMAND, Professor
- Phone Number: +33 4 91 38 79 91
- Email: mrichard@ap-hm.fr
-
Principal Investigator:
- Marie Alteh RICHARD LALLEMAND, Professor
-
Pessac, France, 33604
- Recruiting
- Hôpital Haut-Lévêque
-
Contact:
- Marie Sylvie DOUTRE, Professor
- Email: marie-sylvie.doutre@chu-bordeaux.fr
-
Principal Investigator:
- Marie Sylvie DOUTRE, Professor
-
Quimper, France, 29107
- Recruiting
- Centre Hospitalier de Cornouaille
-
Contact:
- Ingrid KUPFER-BESSAGUET, Doctor
- Phone Number: +33 2 98 52 60 60
- Email: i.kupfer@ch-cornouaille.fr
-
Principal Investigator:
- Ingrid KUPFER-BESSAGUET, Doctor
-
Reims, France, 51 092
- Recruiting
- Hôpital Robert Debré, chu de Reims
-
Contact:
- Philippe BERNARD, Professor
- Phone Number: +33 3 26 78 43 68
- Email: pbernard@chu-reims.fr
-
Principal Investigator:
- Philippe BERNARD, Professor
-
Rouen, France, 76031
- Recruiting
- University Hospital of Rouen
-
Contact:
- Pascal JOLY, Professor
- Phone Number: +33 2 32 88 80 39
- Email: Pascal.Joly@chu-rouen.fr
-
Sub-Investigator:
- Sophie DUVERT LEHEMBRE, Doctor
-
le Mans, France, 72037
- Recruiting
- CH du Mans
-
Contact:
- Hervé MAILLARD, Professor
- Phone Number: +33 2 43 43 43 58
- Email: hmaillard@ch-lemans.fr
-
Principal Investigator:
- Hervé MAILLARD, Professor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient major
Patients with pemphigus vulgaris, diagnosed on a combination of:
- clinical signs and
- histological image above basal epithelial detachment with intra acantholysis,
- direct immunofluorescence showing deposition of Immunoglobulin G and / or C3 to the surface of keratinocytes
- Join a social security scheme
- patient has been informed and have signed consent to participate in the study
Exclusion Criteria:
- Person placed under judicial protection,
- Patient without liberty by administrative or judicial decision,
- Patient participating in another trial for the duration of monitoring.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: prevalent cases
40 prevalent cases correspond to patients with known pemphigus. Emphasis will be on included patients at different times of the course of their disease. 8 incident cases recruited through the center of Rouen and following an intervention program with psychological support and therapeutic education program |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
analysis of vulnerability factors
Time Frame: 12 months
|
evaluation of : perception by the patient of misdiagnosis, perception of a possible difference in assessment of the severity of his illness between himself and healthcare professionals, patient behavior in relation to available information sources, and the influence of information gathered on the illness experience, Patient trajectory during the diagnostic phase using individual interview and questionnaire
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
analysis of vulnerability factors
Time Frame: 6 months
|
evaluation of : perception by the patient of misdiagnosis, perception of a possible difference in assessment of the severity of his illness between himself and healthcare professionals, patient behavior in relation to available information sources, and the influence of information gathered on the illness experience, Patient trajectory during the diagnostic phase using individual interview and questionnaire
|
6 months
|
assessment of anxiety, uncertainty, fear, coping strategies
Time Frame: 12 months
|
assessment of anxiety, uncertainty, fear, coping strategies using individual interview and questionnaire
|
12 months
|
assessment of anxiety, uncertainty, fear, coping strategies
Time Frame: 6 months
|
assessment of anxiety, uncertainty, fear, coping strategies using individual interview and questionnaire
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Pascal Joly, Professor, University Hospital, Rouen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2015
Primary Completion (Anticipated)
May 1, 2018
Study Completion (Anticipated)
November 1, 2018
Study Registration Dates
First Submitted
September 1, 2014
First Submitted That Met QC Criteria
September 8, 2014
First Posted (Estimate)
September 11, 2014
Study Record Updates
Last Update Posted (Actual)
August 30, 2017
Last Update Submitted That Met QC Criteria
August 29, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014/063/HP
- 2014A0067740 (Registry Identifier: RCB number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pemphigus
-
argenxCompletedPemphigus Vulgaris | Pemphigus FoliaceusUnited States, Australia, Bulgaria, China, France, Georgia, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
-
Cabaletta BioRecruitingMucosal -Dominant Pemphigus VulgarisUnited States
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Autoimmunity Centers of ExcellenceTerminatedPemphigus Vulgaris | Pemphigus FoliaceusUnited States
-
argenxCompletedPemphigus Vulgaris | Pemphigus FoliaceusGermany, Hungary, Israel, Italy, Ukraine
-
Cairo UniversityCompletedOral Pemphigus VulgarisEgypt
-
Hoffmann-La RocheAspreva PharmaceuticalsCompletedPemphigus Vulgaris (PV)Turkey, Switzerland, United States, Germany, United Kingdom, Ukraine, Israel, Canada
-
argenxTerminatedPemphigus Vulgaris | Pemphigus FoliaceusUnited States, Germany, Italy, Australia, Bulgaria, China, France, Georgia, Greece, Hungary, India, Israel, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceUnknownPemphigus Vulgaris | Pemphigus FoliaceusFrance
-
Alexion PharmaceuticalsTerminatedPemphigus | Pemphigus Vulgaris | Pemphigus FoliaceusUnited States
-
Principia Biopharma, a Sanofi CompanyPrincipia Biopharma Australia Pty Ltd.CompletedPemphigus VulgarisIsrael, Australia, Greece, Croatia, France
Clinical Trials on psychological support and therapeutic education program
-
University of FreiburgUniversity of Lausanne HospitalsUnknown
-
T.C. ORDU ÜNİVERSİTESİNot yet recruiting
-
Massachusetts General HospitalUnknownPsychological StressUnited States
-
University Hospital, ToulouseActive, not recruiting
-
JOSE MIGUEL MORALES ASENCIOUnknownDiabetes Mellitus, Type 2Spain
-
Institut de Cancérologie de la LoireCompleted
-
Institut de Cancérologie de la LoireCentre Leon Berard; Hospices Civils de LyonUnknown
-
University Hospital, ToulouseCompleted
-
Assistance Publique Hopitaux De MarseilleUnknownType 1 Pediatric DiabetesFrance
-
University Hospital, ToulouseCompleted